The AHR Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by targeted disruption of the AHR gene in the human A-549 cell line. This product provides a heterogeneous loss-of-function model suitable for studying aryl hydrocarbon receptor (AHR) signaling without homogenous or clonal selection, thereby preserving diverse genetic backgrounds within the knockout pool. The polyclonal nature allows researchers to interrogate AHR function in a population that more closely mimics biological variability, making it an invaluable tool for screening and phenotypic analyses.
The host A-549 cell line is a widely used model derived from human lung adenocarcinoma epithelial cells. A-549 cells retain key characteristics of alveolar type II pneumocytes, including surfactant production and a well-characterized response to environmental toxins. Their robust epithelial morphology and stable growth make them an ideal platform for investigating lung adenocarcinoma pathobiology and pulmonary toxicology.
AHR is a ligand-activated transcription factor that mediates cellular responses to diverse ligands such as TCDD, kynurenine, and FICZ. In the cytoplasm, AHR is complexed with HSP90, XAP2, and p23. Upon ligand binding, AHR translocates to the nucleus, heterodimerizes with ARNT, and binds to XREs to regulate target genes. Key downstream targets include CYP1A1, CYP1B1, AHRR, and TIPARP, along with immunoregulatory cytokines IL-22 and IL-10. AHR signaling also influences T cell differentiation, promoting Th17/Treg balance and FoxP3+ regulatory T cell induction, thus linking xenobiotic metabolism with immune modulation.
In the context of A-549 lung adenocarcinoma cells, AHR is a critical mediator of xenobiotic-induced toxicity and carcinogenesis. Knocking out AHR disrupts the cellular response to polycyclic aromatic hydrocarbons and tryptophan metabolites, affecting detoxification pathways and immune-related gene expression. This model enables dissection of AHR??s role in lung cancer progression, where AHR may modulate proliferation, apoptosis, and the tumor microenvironment. Furthermore, the loss of AHR in this epithelial background provides a unique system to explore crosstalk between metabolic detoxification and inflammatory signaling in the lung.
The AHR Knockout A-549 Polyclonal Cells are suited for toxicology, cancer biology, immunology, and drug metabolism research. Typical assays include RT-qPCR for AHR target genes (CYP1A1, CYP1B1, AHRR), CYP1A1 activity assays, western blotting, and immunofluorescence for AHR localization. Further applications encompass XRE luciferase reporter assays, flow cytometry for immune phenotype, and kynurenine production measurement. These polyclonal knockouts support functional genomics, environmental health studies, and therapeutic target validation in lung adenocarcinoma and immune disorders. Contact Ascent Research for details.
